If you've spent any time researching weight loss over the past couple of years, you've almost certainly come across GLP-1 injections. What started as a diabetes treatment has become the most talked-about development in weight management in a generation, with millions of people now using medications like semaglutide and tirzepatide to lose significant amounts of body weight. This guide walks through exactly what these medications are, how they work, what results are realistic, and what to consider before starting.
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of injectable medications that mimic a hormone your gut naturally releases after you eat. That hormone signals to your brain and digestive system that you're full, slows the rate food leaves your stomach, and helps regulate blood sugar. By activating those same receptors, GLP-1 medications essentially amplify your body's own fullness signals.
The first GLP-1 medications, like liraglutide, were developed for type 2 diabetes. Researchers noticed that patients taking them consistently lost weight as a side effect, which led to dedicated weight-management formulations and, eventually, dual-acting medications like tirzepatide that target two hormone pathways instead of one.
This class of medication is fundamentally different from older weight-loss drugs, many of which worked as appetite-suppressing stimulants and carried significant cardiovascular risk or dependency concerns. GLP-1 injections instead work with a hormonal pathway your body already uses, which is a large part of why they've shown a more favorable long-term safety profile in large clinical trial populations and why they've been adopted so broadly by mainstream medicine rather than staying on the fringes of weight-loss treatment.
Rather than acting as a stimulant or fat-burner, GLP-1 medications work primarily by changing appetite and satiety signaling. In practice, that tends to show up as:
Most people are prescribed a low starting dose that is gradually increased — usually every four weeks — up to a target maintenance dose. This slow titration schedule is the main strategy providers use to minimize gastrointestinal side effects like nausea.
Three GLP-1 or dual-agonist medications currently carry FDA approval specifically for chronic weight management: Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide). Each is delivered by subcutaneous injection, with Wegovy and Zepbound dosed once weekly and Saxenda dosed daily.
Many telehealth providers, including NovaSlim Rx, PureForm Health, and VitalShape MD, also offer compounded semaglutide or tirzepatide. Compounded medications are prepared by licensed pharmacies and can be a more accessible option when brand-name supply or cost is a barrier, but they are not individually reviewed by the FDA for safety, quality, or effectiveness the way the approved brand-name products are. If you're considering a compounded option, ask your provider directly about which pharmacy prepares it and how it's dosed.
Cost is often the deciding factor between these paths. Brand-name medications typically carry a higher list price but may be partially covered by insurance, especially if your diagnosis meets a payer's criteria for weight-management coverage. Compounded versions are usually priced lower and billed as a flat monthly membership through the telehealth provider, which can make budgeting simpler even without insurance. Neither path is inherently "better" — it comes down to your coverage, budget, and comfort level, which is worth discussing openly with your provider during your first consultation.
Appetite suppression is often noticeable within the first week or two, though visible weight loss typically takes a bit longer to show up on the scale. In the STEP 1 clinical trial, participants taking semaglutide lost an average of approximately 15% of their body weight over 68 weeks when the medication was combined with diet and exercise counseling. Tirzepatide trials have shown even larger average losses, with many participants losing 20% or more of their starting body weight over roughly 72 weeks.
Results vary widely based on starting weight, dose, consistency, and lifestyle factors. Weight loss is typically gradual and steady rather than immediate — most people see the bulk of their results emerge over several months, not weeks.
It's also common to hit a plateau at some point during treatment, particularly after the first several months. This doesn't necessarily mean the medication has stopped working; it often reflects the body settling into a new equilibrium, and providers may respond by adjusting your dose, reviewing your nutrition, or simply reassuring you that plateaus are a normal part of the process rather than a sign to abandon treatment. Tracking measurements beyond the scale — energy levels, clothing fit, blood pressure, and lab markers — can also give a fuller picture of progress than weight alone.
"Results vary significantly from person to person — consistency with dosing and lifestyle changes tends to be the biggest predictor of long-term success." — WeightBloomX Editorial Team
The most common side effects are gastrointestinal: nausea, mild vomiting, constipation, diarrhea, and stomach discomfort, especially during dose increases. These tend to ease as your body adjusts. Less common but more serious risks are typically screened for during your intake with a licensed provider, including a personal or family history of certain thyroid cancers and pancreatitis.
GLP-1 injections are generally intended for adults with a BMI of 30 or higher, or a BMI of 27 or higher combined with a weight-related condition such as high blood pressure or type 2 diabetes. A licensed provider should always confirm eligibility through a health screening before you start treatment — this isn't a medication to self-prescribe or source outside a legitimate pharmacy.
A thorough intake typically includes a review of your medical history, current medications, and any personal or family history of thyroid or pancreatic conditions, plus a conversation about your weight-loss goals and expectations. Reputable providers will decline to prescribe if you don't meet clinical criteria, rather than approving anyone who completes a questionnaire — that willingness to say no is itself a good sign of a provider taking medical oversight seriously.
GLP-1 weight loss injections represent one of the most effective tools available for chronic weight management, with clinical results that meaningfully outperform most previous pharmaceutical options. They aren't a shortcut — they work best paired with sustainable diet and activity changes, and they require an ongoing relationship with a licensed provider to manage dosing and monitor side effects. If you're considering starting, take the time to compare providers on transparency, medical support, and pricing before committing.
This article is for informational purposes only and is not medical advice. Talk to a licensed healthcare provider to determine whether a GLP-1 medication is appropriate for you.